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BACKGROUND: Response assessment in advanced pancreatic cancer (APC) is difficult and predictive markers are needed. There are
insufficient data on the value of carbohydrate antigen 19–9 (CA 19-9) and cytostatic-targeted therapies. Axitinib, a selective vascular
endothelial growth factor (VEGF) receptors 1, 2, 3 inhibitor, may increase overall survival (OS) in APC.
METHODS: We assessed serum CA 19-9, clinical outcomes and diastolic blood pressure (dBP) in APC patients receiving gemcitabine
plus axitinib (GemþA) or gemcitabine alone.
RESULTS: In the total population (N¼95), median OS was significantly longer in patients with baseline CA 19-9 values at or below the
median than in those with values above it (12.2 months [95% confidence interval (CI), 8.6–16.6%] vs 5.0 months [95% CI,
3.9–5.7%]; Po0.0001). This also reached significance in the GemþA arm (median OS, 12.5 months [95% CI, 8.6–16.6%] vs
4.9 months [95% CI, 3.6–5.6%]; Po0.0001). Patients with any dBP490mmHg had significantly longer OS than those who did not.
However, there was no predictive significance of CA 19-9.
CONCLUSION: Baseline CA 19-9 levels had prognostic value for OS, but caution is advised in interpreting CA 19-9 as a predictive
biomarker for novel cytostatic agents such as VEGF-targeted therapies in phase II studies.
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Monitoring objective responses to systemic therapy using con-
ventional imaging can be difficult in patients with advanced
pancreatic cancer (APC) whose disease is located predominantly at
the primary site (Rothenberg et al, 1996). These techniques may
underestimate the response to systemic therapy, as the image
incorporates tumour desmoplasia, which is prevalent in pancreatic
tumour growth and is unlikely to be affected by systemic therapy.
In addition, favourable objective response rates in early studies
of new targeted agents or combinations have not been predictive
of benefit in phase III studies (Xiong et al, 2004; Kindler et al,
2005, 2007; Phillip et al, 2007). Alternative predictive methods for
monitoring therapy benefit and predicting prognosis in early
phase studies are urgently needed especially as vascular endo-
thelial growth factor (VEGF)-targeted strategies do not seem to
contribute significantly to classical objective assessments in terms
of complete responseþpartial response (PR).
As its initial characterisation in 1979 (Koprowski et al, 1979,
1981), the role of the tumour-associated carbohydrate antigen 19-9
(CA 19-9) as a serum marker for tumours has been widely studied,
particularly in patients with pancreatic cancer. CA 19-9 is the
sialylated Lewis (Le)
a blood group antigen (Magnani et al, 1982),
and cannot be synthesised in individuals with a Le
a–b– phenotype
(5% of the population) (Tempero et al, 1987). Serum CA 19-9
seems to show greatest specificity for pancreatic cancer, being
elevated in approximately 70–80% of patients (Del Villano et al,
1983; Jalanko et al, 1984; Haglund et al, 1986; Safi et al, 1989,
1997). Despite these findings, CA 19-9 is not currently recom-
mended as a routine diagnostic or screening test for pancreatic
cancer (Frebourg et al, 1988; Locker et al, 2006), as its specificity
and sensitivity are inadequate for accurate diagnosis. Serum CA
19-9 may also be increased in a number of benign conditions,
including benign hepatobiliary diseases, and in biliary obstruction
(Haglund et al, 1986; Frebourg et al, 1988).
The prognostic value of peri-operative CA 19-9 levels and its
role as an indicator of asymptomatic recurrence have been
investigated in patients with resectable pancreatic cancer (Jiang
et al, 2004; Ferrone et al, 2006), and a recent phase III trial
confirmed the prognostic value of post-resection CA 19-9 levels
in patients undergoing surgery with curative intent (Berger et al,
2008). However, the greatest potential lies in exploiting CA 19-9
as a biomarker in patients with advanced inoperable pancreatic
cancer, who comprise at least 80% of those diagnosed (National
Cancer Institute, 2008). Several studies have found baseline CA
19-9 levels to be an independent prognostic factor for survival in
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spatients with APC (Saad et al, 2002; Micke et al, 2003; Louvet et al,
2005; Maisey et al, 2005; Hess et al, 2008; Park et al, 2008). An
association between reduction in CA 19-9 levels during treatment
and prolonged survival has also been reported (Halm et al, 2000;
Saad et al, 2002; Stemmler et al, 2003; Ziske et al, 2003; Ko et al,
2005). However, none of the large randomised studies has reported
on the specific impact of targeted cytostatic therapies on CA 19-9
levels as a predictive biomarker.
This retrospective analysis describes the kinetics and the
prognostic value of CA 19-9 and investigates the association with
clinical outcome and diastolic blood pressure (dBP) in patients
with APC receiving gemcitabine plus axitinib (an oral, potent
inhibitor of VEGF receptors [VEGFR] 1, 2, 3; GemþA) or
gemcitabine alone (Gem) in a randomised phase II trial (Spano
et al, 2008). We have already shown that dBP may be a predictive
biomarker in those benefiting from axitinib (Spano et al, 2008); in
the present analysis, we also explore further the correlation
between changes in CA 19-9 levels and dBP.
MATERIALS AND METHODS
Patients
Eligible patients were aged X18 years with histologically/
cytologically confirmed, locally advanced (unresectable) or meta-
static pancreatic adenocarcinoma, and had not received any prior
systemic therapy for advanced disease. Other inclusion criteria
included Eastern Cooperative Oncology Group performance status
(ECOG PS) of 0–2 and adequate hepatic, renal and bone marrow
function (bilirubin p1.5 the upper limit of normal). The absence
of biliary obstruction at baseline minimised the possibility of false
reflection of disease activity. Patients were excluded if they had
received prior treatment with gemcitabine or anti-angiogenic
agents and were also excluded in the case of pregnancy or
lactation, prior cerebrovascular accident, major surgery within
4 weeks of starting treatment, brain metastases, active second
malignancy, uncontrolled intercurrent illness, urine protein
X500mg in 24h or ongoing uncontrolled hypertension. Patients
with current or anticipated need for cytochrome P450 CYP1A2
inducers or CYP3A4 inhibitors or inducers were not eligible. The
phase II study was approved by the institutional review board at
each of the participating centres and was performed in accordance
with the Declaration of Helsinki and Good Clinical Practice
Guidelines.
Study design and treatment
The phase II, open-label, multicentre study was designed to
compare overall survival (OS) in patients with APC who were
randomly assigned in a 2:1 ratio to receive GemþA or Gem.
Stratification factors included disease extent (locally advanced vs
metastatic) and ECOG PS (0/1 vs 2). Tumour response was
determined using Response Evaluation Criteria in Solid Tumors
(RECIST) (Therasse et al, 2000). Gemcitabine was administered
at a dose of 1000mgm
–2 by 30-min intravenous infusion on
days 1, 8 and 15 in 4-week cycles in both treatment arms; those
randomised to GemþA also received axitinib 5mg twice a day,
continuously. Toxicity-based dose reductions were pre-specified
in the protocol.
Assessment of CA 19-9
Blood samples for measurement of CA 19-9 were collected at
baseline (within 14 days before the start of treatment) and at least
every 4 weeks during treatment with either GemþA or Gem.
CA 19-9 levels were determined at individual trial centres using
each centre’s standard assay and methodology. Most frequently
reported reference range was 0–37Uml
–1. CA 19-9 measurements
were routinely performed at the same laboratory, ensuring reason-
able intra-patient consistency.
Assessment of blood pressure
Blood pressure was measured as part of a physical examination
(which also included cardiac function and laboratory analyses of
haematology and urinalysis) at baseline, with repeated assessments
made on day 1 of each gemcitabine cycle in both treatment arms.
A follow-up assessment was carried out 28 days after the last
treatment dose.
Statistical considerations
Overall study sample size was determined by the primary end
point of OS. Descriptive statistics were used to record baseline CA
19-9 levels and the percentage change of this biomarker relative
to baseline. In successive analyses, patients in each treatment
arm were grouped according to the maximum level of CA 19-9
reduction (or response) during treatment (X25% decline vs o25%
decline; X50% decline vs o50% decline). Sustained biomarker
decline (i.e. confirmation by two measurements spaced at least
28 days apart) was not required. Different to the analysis by
Ko et al (2005), patients with only one CA 19-9 measurement were
excluded from the CA 19-9 reduction analysis as non-responders.
These were not categorised as non-decliners.
Median baseline CA 19-9 level was ascertained for each treat-
ment arm. The log-rank test was used to compare OS in patients
with baseline levels that fell above or below the median level (based
on the analysis by Maisey et al, 2005), and to compare OS and
progression-free survival (PFS) in patient groups below and above
each of the above CA 19-9 response thresholds, by treatment arm.
The Kaplan–Meier method was used to generate survival curves
according to baseline CA 19-9 levels and to CA 19-9 response
during treatment. A Cox proportional hazards model using a
X25% reduction in CA 19-9 level as a time-dependent covariate
was used to examine the relationship between survival and reduced
CA 19-9 levels with time.
Patients were also grouped according to maximum dBP achieved
on study (o90mmHg vs X90mmHg). Within the subgroups, the
median drop in CA 19-9 from baseline to nadir was measured and
compared using a Wilcoxon rank sum test. The Kaplan–Meier
method was used to estimate median OS for each subgroup.
RESULTS
Of the 103 patients enrolled in the study, 95 patients (65 and
30 patients randomised to GemþA and to Gem, respectively) had
a baseline CA 19-9 sample higher than the reference range (based
on the lower limit) and were considered eligible for analysis.
Patient baseline characteristics were well matched between the
treatment arms (Table 1).
CA 19-9 kinetics
Median baseline CA 19-9 values were 1096.0Uml
–1 (range,
1.6–352179.6) and 1709.5Uml
–1 (range, 16.0–122163.0) in the
GemþA and Gem arms, respectively. Fifty-three patients random-
ised to the GemþA arm had X1 CA 19-9 measurement during
treatment and achieved a median nadir value of 136.0Uml
–1
(range, 1.0–40175.0); the median time to nadir was 70 days (range,
15–251). Among the 22 patients with CA 19-9 measurements
during treatment with Gem, the median nadir was 471.5Uml
–1
(range, 0.8–53115.3), with a median time to nadir of 79.5 days
(range, 26–287). In the GemþA and Gem arms, 37 patients (86%)
and 13 patients (65%), respectively, achieved a X25% reduction
in the level of CA 19-9 during treatment when compared with
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sbaseline; these proportions were not significantly different
(P¼0.092). Among patients on the GemþA arm, CA 19-9 levels
during treatment fell by X50% compared with baseline in
31 patients (72%) and by X75% in 15 patients (35%); 12 patients
(60%) and 6 patients (30%) on the Gem arm achieved on-
treatment CA 19-9 reductions of X50% and X75%, respectively.
Differences were not statistically significant between treatment
arms. Twenty patients had CA 19-9 measurements only at base-
line and, per definition, were classified as non-responders and
excluded from the CA 19-9 analysis.
Relationship between CA 19-9 and clinical efficacy
In the overall population (i.e. both treatment groups combined),
median OS was significantly longer in patients with a baseline
CA 19-9 level equal to or below the median value than in patients
with baseline CA 19-9 above the median value (median OS,
12.2 months [95% confidence interval (CI), 8.6–16.6 months] vs
5.0 months [95% CI, 3.9–5.7 months]; Po0.0001; Figure 1A).
Similarly, in the GemþA arm, patients with a baseline CA 19-9
level equal to or below the median value for that arm lived
significantly longer than patients with baseline CA 19-9 above the
median value (median OS, 12.5 months [95% CI, 8.6–16.6 months]
vs 4.9 months [95% CI, 3.6–5.6 months]; Po0.0001; Figure 1B).
In patients treated with Gem, OS seemed longer among those
with a baseline CA 19-9 level equal to or below the median value;
however, the difference did not reach significance probably
because of the limited sample size (median OS, 11.6 months
[95% CI, 3.8–14.7 months] vs 5.4 months [95% CI, 3.9–7.7
months]; P¼0.1109; Figure 1C).
For the population as a whole, a non-significant trend to longer
OS was observed in patients achieving a reduction of X25% in
CA 19-9 levels during treatment than in those patients with
CA 19-9 reductions below this threshold (median OS, 8.8 months
vs 5.2 months; P¼0.1779), as well as longer PFS (median PFS,
6.7 vs 2.5 months; P¼0.1002). In the GemþA arm, OS and
PFS again showed a non-significant trend, but in the Gem arm,
the differences were significant despite the smaller numbers of
patients (Table 2; Figures 2 and 3). Five patients receiving GemþA
achieved a confirmed PR per RECIST; four of these patients had
a X85% reduction in CA 19-9 levels during treatment and one a
54% reduction. One patient receiving Gem experienced a PR and
had a 52% reduction in CA 19-9 levels during treatment.
We also analysed the relationship between dBP, response and
serum CA 19-9. dBP seemed to be a strong response predictor in
the GemþA arm, but not the Gem arm. The median percentage
drop to the CA 19-9 nadir was 59.9% in the group that had any dBP
o90mmHg, and 61.9% in the group that had any diastolic reading
X90mmHg (Table 3; P¼0.5201 for difference in medians). Given
the small sample sizes, we were not able to detect any statistical
interaction between dBP and CA 19-9 for OS. Analysis of kinetic
differences, distribution or volatility (by assessing inter-quartile
ranges) in the two groups was unable to show any obvious differ-
ences (data not shown).
DISCUSSION
The advances in the treatment of pancreatic cancer have been
extremely disappointing. The first series of randomised trials
with novel agents targeting specific molecular pathways have not
clinically improved patient outcomes. Therefore, a need exists for
biomarkers to test in the randomised phase II setting to inform
phase III trial design and to enable better understanding of how
best to integrate these novel agents into treatment approaches.
CA 19-9 has prognostic and predictive value with conventional
cytotoxic agents, but little is known about its kinetics with the
newer class of cytostatic treatments.
This retrospective analysis is based on prospectively collected
data from patients with APC, randomised to receive either GemþA
or Gem (Spano et al, 2008). Several molecularly targeted therapies
are currently being assessed in patients with pancreatic cancer,
but, to our knowledge, this is the first published analysis of its
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Figure 1 CA 19-9 as a prognostic factor: Kaplan–Meier curves for OS
according to baseline CA 19-9 value (p and 4 the median) (A) in both
treatment groups combined, (B) for the GemþA arm only and (C) for
the Gem arm only.
Table 1 Patient baseline characteristics
Gem+A (n¼65) Gem (n¼30)
Median age (range), years 65.0 (44–81) 62.5 (36–78)
Gender (male/female), n 32/33 14/16
ECOG PS, n (%)
p1 59 (91) 27 (90)
2 6 (9) 3 (10)
Disease stage, n (%)
Locally advanced
29 (45)
10 (33)
Metastatic 36 (55) 20 (67)
Abbreviation: ECOG PS¼Eastern Cooperative Oncology Group performance status.
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stype in patients receiving a potent VEGFR inhibitor that seems
to influence OS. We had earlier shown that achieving a dBP
X90mmHg at any time during GemþA treatment seemed to have
great influence on patient outcome: in a post hoc exploratory
analysis, median OS in the GemþA group was 13.0 (95% CI,
8.5–16.6) months for the 27 patients with at least one dBP
measurement X90mmHg during treatment in clinic, compared
with 5.6 (95% CI, 4.8–7.2) months for the 34 patients without
any dBP measurement X90mmHg during treatment and with X1
blood pressure measurement after cycle 1, day 1 (Spano et al,
2008). Patients in the GemþA group without any dBP measure-
ment X90mmHg had similar survival to patients in the Gem
group.
In our study, CA 19-9 measurements were not centralised, but
were performed at each centre independently (ensuring reasonable
intra-patient consistency), with no requirement to use a standard-
ised assay. This is a limitation in the context of our retrospective
study. CA 19-9 values during treatment were available for only
75 of the 95 patients with baseline CA 19-9 levels. Although this
is also a limitation of our analysis, other studies have reported
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Figure 2 CA 19-9 as a predictor of treatment response: Kaplan–Meier
curves for OS according to decline in CA 19-9 value (X and o25%
compared with baseline) during treatment with (A) GemþA and
(B) Gem alone.
Table 2 Median overall survival (OS) and median progression-free survival (PFS) according to percentage decrease in CA 19-9 compared with baseline
by treatment group
Gem+A Gem
Decrease in CA 19-9 oThreshold XThreshold P* oThreshold XThreshold P*
Median OS (months)
25% 9.5 8.6 0.8989 4.2 10.3 0.0290
50% 6.0 9.0 0.3392 4.7 9.0 0.1828
Median PFS (months)
25% 12.2 6.3 0.6237 1.8 6.7 o0.0002
50% 5.3 7.6 0.4154 2.2 6.7 0.0370
*P-value for difference between median OS (or PFS) for patients with a CA 19-9 response above or below the indicted threshold; thresholds determined by grouping patients in
each treatment arm according to the maximum level of CA 19-9 reduction (or response) during treatment (X25% decline vs o25% decline; X50% decline vs o50% decline).
A time-dependent Cox proportional hazards model, which statistically adjusts for the confounding effect of time to CA 19-9 nadir on survival, was used.
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Figure 3 CA 19-9 as a predictor of treatment response: Kaplan–Meier
curves for OS according to decline in CA 19-9 value (X and o50%
compared with baseline) during treatment with (A) GemþA and
(B) Gem alone.
Table 3 Change in diastolic blood pressure versus median percentage
drop to CA 19-9 nadir
Change in diastolic blood
pressure during treatment
o90mmHg
(n¼24)
X90mmHg
(n¼18)
Median drop to CA 19-9 nadir (%) 59.9 61.9
Median (95% confidence interval) overall
survival (months)
5.6 (4.8–9.2) 12.0 (9.0–14.1)
CA 19-9 in pancreatic cancer with axitinib/gemcitabine
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ssimilar or even greater drop-out rates (Maisey et al, 2005; Hess
et al, 2008).
In agreement with earlier published reports (Saad et al, 2002;
Micke et al, 2003; Louvet et al, 2005; Maisey et al, 2005; Hess
et al, 2008; Park et al, 2008), we found that baseline CA 19-9 levels
were prognostic for survival in the whole group; patients with
baseline CA 19-9 values at or below the median for the popula-
tion lived significantly longer than those with baseline values
above the median. This was true for the population overall
(12.2 months vs 5.0 months; Po0.0001) and reached significance
in the GemþA arm (Po0.0001), but not in the Gem arm, although
numerical values were similar. This may be due to longer survival
in the GemþA arm, or possibly because of the lower patient
numbers in the Gem arm. Our study also showed that declining
CA 19-9 levels during treatment may be associated with favour-
able patient outcome, but only in the Gem arm. Using thresholds
of 25% and 50% reduction in CA 19-9 levels compared with
baseline, OS and PFS were both significantly longer in patients
receiving Gem with a X25% or X50% decline in CA 19-9 than
in those with less decline. In the GemþA arm, although there
was a trend to longer OS and PFS, these were not statistically
significant. Little is known about the CA 19-9 volatility on dis-
continuation of novel drugs. There seems to be rapid rebound
phenomenon on discontinuation of vascular-targeted agents such
as bevacizumab in other disease settings. One hypothesis is that
increased volatility in serum biomarkers when temporarily dis-
continuing therapy (because of toxicities or lack of compliance)
may confound statistical analysis. In this study, we attempted to
investigate this possibility, but could not find evidence to support
the hypothesis.
Another possibility is that cytostatic agents have a different
effect on pancreatic cancer cells. Supporting this hypothesis,
patients achieving objective tumour responses, whether treated
with GemþA or Gem, all experienced a decline in CA 19-9 of
at least 50% when on treatment. A similar association between
tumour response and CA 19-9 decline has been reported elsewhere
(Stemmler et al, 2003; Ziske et al, 2003; Ko et al, 2005; Hess et al,
2008). Our data concur with those of others that suggest that
CA 19-9 decline in the presence of objective radiological responses
is potentially a predictive indicator of clinical benefit.
CA 19-9 levels tend to increase with stage of pancreatic cancer
(Micke et al, 2003; Jiang et al, 2004), but vary widely, both inter-
and intra-patient (Micke et al, 2003; Ziske et al, 2003; Hess et al,
2008; Park et al, 2008). Our study seems to support this, showing
an inverse relationship between CA 19-9 and a more advanced
phase of disease. Researchers have commonly used the median
baseline CA 19-9 level of the study population as a threshold
for dividing patients with APC into groups for survival com-
parisons (Saad et al, 2002; Micke et al, 2003; Maisey et al, 2005;
Hess et al, 2008; Park et al, 2008). The wide variation in baseline
CA 19-9 levels makes selection of an absolute threshold for
this type of analysis somewhat arbitrary. However, as the data
regarding the importance of baseline CA 19-9 as an independent
prognostic factor for survival is increasing for a range of
treatments (Micke et al, 2003; Louvet et al, 2005; Maisey et al,
2005; Hess et al, 2008), an absolute threshold value would be
valuable to enable separation of different prognostic subgroups,
which in turn will allow prospective determination of prognosis
for an individual patient. As discussed by Boeck et al (2006), this
absolute threshold value could be selected only by conducting a
prospective clinical trial that prospectively defines it (e.g. selecting
an absolute CA 19-9 threshold of 1000Uml
–1 for patients with
metastatic disease).
Several studies have shown that an early CA 19-9 response
(defined variously as a decrease of 420–50% in CA 19-9
compared with baseline within the first 6–8 weeks of treatment)
is associated with significantly longer survival and/or is an
independent predictor of survival on multivariate analysis (Halm
et al, 2000; Stemmler et al, 2003; Ziske et al, 2003; Maisey et al,
2005). In our analysis, CA 19-9 response was not time defined, but
an association with survival was nonetheless observed, similar to
that reported by Ko et al (2005). The median time to CA 19-9 nadir
in our study included a wide range (70 days; range, 15–251; and
79.5 days; range, 26–287 on the GemþA and Gem arms,
respectively) and was longer than the 6–8 weeks used in the
definition of ‘early response’ as described above. The effect of
the difference in definition of CA 19-9 response (time to nadir) on
the analyses (association between CA 19-9 response and patient
outcome) is unclear. Patients who do not meet RECIST criteria
may have a CA 19-9 reduction and contribute to prolonged
survival as well as the time to CA 19-9 nadir. Furthermore, the
tendency of targeted biologics to prevent tumour progression
(i.e. cytostatic vs cytotoxic mechanisms), not revealed by RECIST
criteria, may confound this phenomenon.
A recent analysis of a large cohort of patients (n¼247 with
baseline CA 19-9 levels; n¼175 with baseline and at least
one follow-up value during treatment) entered in a randomised,
controlled clinical trial found no significant difference in survival
between patients achieving an early CA 19-9 response (X50%
decrease in CA 19-9 at day 42) and non-responders (Hess et al,
2008). Equally, there was no significant survival difference between
responders and non-responders at CA 19-9 nadir; median time
to nadir (63 days; range, 7–145) was similar to that in our study,
although with a smaller range. The findings from this study,
which eliminated guarantee-time bias (i.e. to eliminate the impact
of survival time on the classification of responders and non-
responders), seem to indicate that there may not be a prognostic
link between CA 19-9 response and OS. However, when the same
data were analysed using a Cox-regression model, a borderline
significant association between CA 19-9 response and survival was
noted (Hess et al, 2008). A similar analysis conducted in this study
confirms this result and highlights that the wide variation in time
to achieve CA 19-9 nadirs delimits choosing a specific early time
point for analysis.
Despite its frequent use in clinical practice, CA 19-9 kinetics
during therapy needs further validation in the context of random-
ised studies as a potential early response marker. Inclusion of
CA 19-9 measurements in phase III trials would be useful to
confirm the preliminary data presented in this study. Currently,
CA 19-9 may be of use as an additional tool, in conjunction with
imaging and clinical assessment of patient condition, to guide
treatment decisions in an individual patient. Given the apparent
significance of baseline CA 19-9 in patient prognosis, there is a
strong case for it to be used as a stratification factor in random-
ised trials in patients with APC.
In summary, this study has shown a correlation between
baseline CA 19-9 levels and survival and confirms its value as a
prognostic factor in a randomised phase II setting.
However, although CA 19-9 may be a predictive factor for
response to gemcitabine treatment, it is less clear whether
it can be incorporated in studies with novel-targeted agents,
which are cytostatic as opposed to cytotoxic. This is the first
study of its value in a randomised setting with a novel VEGF
inhibitor; our data suggest that more work is needed to validate
CA 19-9 as a predictive marker with novel agents. We advise
caution in using CA 19-9 in phase II settings as a response
biomarker to predict efficacy and as an aid in selection of agents
for phase III studies.
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